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Behavioral/Systems/Cognitive
cAMP Response Element-Binding Protein Deficiency Allows
for Increased Neurogenesis and a Rapid Onset of
Antidepressant Response
Tamar L. Gur,1 Alana C. Conti,1 Jessica Holden,1 Anita J. Bechtholt,2 Tiffany E. Hill,2 Irwin Lucki,1,2 Jessica E. Malberg,3
and Julie A. Blendy1
Departments of 1Pharmacology and 2Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, and 3Neuroscience
Discovery, Wyeth Research, Princeton, New Jersey 08852
cAMP response element-binding protein (CREB) has been implicated in the molecular and cellular mechanisms of chronic antidepres-
sant (AD) treatment, although its role in the behavioral response is unclear. CREB-deficient (CREB mutant) mice demonstrate an
antidepressant phenotype in the tail suspension test (TST) and forced-swim test. Here, we show that, at baseline, CREBmutant mice
exhibited increased hippocampal cell proliferation and neurogenesis compared with wild-type (WT) controls, effects similar to those
observed inWTmice after chronic desipramine (DMI) administration. Neurogenesis was not further augmented by chronic DMI treat-
ment in CREBmutantmice. Serotonin depletion decreased neurogenesis in CREBmutantmice toWT levels, which correlated with
a reversal of the antidepressant phenotype in the TST. This effect was specific for the reversal of the antidepressant phenotype in these
mice, because serotonin depletion did not alter a baseline anxiety-like behavior in CREBmutant mice. The response to chronic AD
treatment in the novelty-induced hypophagia (NIH) testmay rely on neurogenesis. Therefore, we used this paradigm to evaluate chronic
AD treatment in CREBmutant mice to determine whether the increased neurogenesis in these mice alters their response in the NIH
paradigm.Whereas bothWT and CREBmutantmice responded to chronic AD treatment in the NIH paradigm, only CREBmutant
mice responded to acute AD treatment. However, in the elevated zero maze, DMI did not reverse anxiety behavior in mutant mice.
Together, these data show that increased hippocampal neurogenesis allows for an antidepressant phenotype as well as a rapid onset of
behavioral responses to AD treatment.
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Introduction
Antidepressant (AD) treatment involves amelioration of symp-
toms over the course of weeks or months (Wong and Licinio,
2001). Chronic exposure to AD is accompanied by transcrip-
tional and cellular modulation, occurring on a later timescale
than changes in monoamine levels and consistent with the onset
of the relief of symptoms (Frazer and Benmansour, 2002; Nestler
et al., 2002; Young et al., 2002; Carlezon et al., 2005; Blendy,
2006). In particular, the transcription factor cAMP response
element-binding protein (CREB) is upregulated after chronic AD
treatment; increases in CREB mRNA and protein, or phosphor-
ylation of CREB have been shown in the hippocampus after
chronic, but not acute AD administration (Nibuya et al., 1996;
Thome et al., 2000; Blom et al., 2002; Tiraboschi et al., 2004).
The significance of CREB regulation in mechanisms through
which chronic AD treatment produces symptomatic relief is un-
known. Hippocampal atrophy is hypothesized to be one contrib-
uting factor to the affective and cognitive impairments observed
in depression (Watanabe et al., 1992; Stein-Behrens et al., 1994;
Magarinos et al., 1996; Sheline, 1996; McEwen, 1999; Sheline et
al., 2003). AD drugs that increase neurogenesis in the dentate
gyrus of the adult hippocampus plausibly counteract this pathol-
ogy of depression (Malberg et al., 2000; Czeh et al., 2001; Manev
et al., 2001; Santarelli et al., 2003; Kodama et al., 2004; Sairanen et
al., 2005). CREB appears to play a role in neurogenesis, because
immature neurons in the adult hippocampus express phosphor-
ylated CREB (Nakagawa et al., 2002b). Furthermore, transgenic
mice expressing a dominant-negative CREB mutation in the hip-
pocampus demonstrated a reduction in neurogenesis (Nakagawa et
al., 2002a). The concurrent increases of both CREB and neurogen-
esis in the hippocampus in response to chronic AD treatment sug-
gest that CREBmay regulate hippocampal neurogenesis.
Although CREB may mediate molecular and cellular changes
induced by AD treatment, its role in modulating behavioral
responses to chronic treatment is still unclear. We previously
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reported that mice deficient in CREB (CREB  mutant)
(Hummler et al., 1994; Blendy et al., 1996) show a baseline de-
crease in immobility in the forced-swim test (FST) and tail sus-
pension test (TST), behavioral models commonly used to evalu-
ate AD efficacy (Lucki, 2001; Cryan et al., 2005). However,
immobility is further decreased with AD treatment (Conti et al.,
2002), suggesting that this acute behavioral response is mediated
by a CREB-independentmechanism.We examined neurogenesis
in these animals and showed that CREBmutant mice had in-
creased levels of hippocampal neurogenesis at baseline. Reduc-
tions in neurogenesis achieved by serotonin depletion in mutant
animals correlated with a reversal in the baseline antidepressant
phenotype of CREB mutant mice in the TST, whereas wild-
type (WT) mice did not show a change in either parameter. The
novelty-induced hypophagia (NIH) and novelty suppressed
feeding (NSF) paradigms are two closely related paradigms that
are responsive to chronic antidepressant treatment, and this be-
havioral response has been correlated with neurogenesis. In these
paradigms, latency to consume food in a novel environment is
measured and chronic but not acute AD treatment, as well as
acute benzodiazepine treatment, reduces the latency to feed in a
novel environment (Merali et al., 2003; Dulawa and Hen, 2005).
This effect of chronic antidepressant treatment, however, is di-
minished when neurogenesis is impaired (Santarelli et al., 2003).
This result suggests that the increase in neurogenesis associated
with chronic antidepressant treatment is required for the behav-
ior associated with this paradigm. Therefore, we examined the
effect of chronic DMI administration using the NIH paradigm.
We found that, whereas both WT and CREB mutant mice
responded to chronic AD treatment in this paradigm, only
CREB mutant mice responded to acute treatment. Together,
these findings suggest that, in the absence of CREB throughout
development, an antidepressant phenotype emerges on both a
cellular and behavioral level.
Materials andMethods
Animals. CREB mutant mice were backcrossed to the inbred mouse
strains 129SvEv and C57BL/6 for 20 generations. For these experi-
ments, WT and CREBmutants were F1 hybrids obtained from cross-
ing mice heterozygous for the CREB mutation from each strain. Mice
(3–6 months of age; 20–40 g) were group housed and maintained on a
12 h light/dark cycle with food and water available ad libitum in accor-
dance with the University of Pennsylvania Animal Care and Use Com-
mittee. For the NIH paradigm, mice were housed in groups of two. All
experimental testing sessions were conducted between 9:00 A.M. and
3:00 P.M., with animals randomly assigned to treatment conditions and
tested in counterbalanced order.
Drugs. p-Chlorophenylalanine methyl ester hydrochloride (PCPA), a
tryptophan hydroxylase inhibitor (250 mg/kg, i.p.) (Sigma, St. Louis,
MO) was dissolved in deionized water and injected twice daily for 3 d.
The last dose was administered 18 h before behavioral testing or killing
for neurogenesis. Desipramine (DMI) (12.5 mg/kg) (Sigma) was pre-
pared immediately before use and injected intraperitoneally using a vol-
ume of 10 ml/kg. The dose was calculated as milligrams per kilogram of
the salt form and was dissolved in 0.9% saline. For acute treatment, mice
were injected with DMI or 0.9% saline in the morning and afternoon of
the day before, andmorning of the day of testing, for a total of three doses
before exposure to the zero maze or NIH paradigm. For chronic treat-
ment, mice were treated with DMI or saline twice daily for 3 weeks.
Tail suspension test. Eighteen hours after the final injection of saline or
PCPA, mice were individually suspended by the tail to a horizontal ring-
stand bar (distance from floor, 35 cm) using adhesive tape affixed 2 cm
from the tip of the tail. Mice demonstrated several escape-oriented be-
haviors interspersed with bouts of immobility as the session progressed.
A 6min test sessionwas videotaped and scored by a trained observer who
was blind to the experimental conditions. The behavioralmeasure scored
was the duration of “immobility,” defined as the time when mice were
judged to cease escape-motivated behaviors.
Elevated zero maze. The zero maze (Stoelting, Wood Dale, IL) was
elevated 24 inches from the ground and consisted of two open areas (wall
height, 0.5 inches) and two closed areas (wall height, 12 inches). Each
mouse was placed in the closed area and the duration of testing was 300 s.
The Viewpoint Tracking System (Viewpoint, Champagne auMont d’Or,
France) was used to video record and register the time spent in the open
areas and the number of entries into each area. Ethological parameters
[rearing, stretch-attend-posture (SAP), and head-dips] were scored
manually. The test was performed in dim lighting. Mice were acclimated
to the room for 1 h before testing. For the PCPA experiment, mice re-
ceived the final dose of PCPA 18 h before testing. For the DMI experi-
ment, mice received a total of three doses of DMI before testing (9:00
A.M. and 5:00 P.M. of the day before testing, and 9:00 A.M. on test day)
1–4 h before testing.
Novelty-induced hypophagia. For 1 week before the training period,
and for the duration of the experiment, mice were housed in groups of
two. Training consisted of daily sessions in whichmice were exposed to a
highly palatable food (peanut butter chips; Nestle, Glendale, CA) in a
clear plastic dish. Plastic dividers were placed inside each cage to separate
the mice during the training and home cage testing periods. Mice were
acclimated for 1 h before placement of food. Food was placed in the cage
for 15 min and latency to consume was measured. By the 12th day, a
baseline latency to approach the food dish was reached such that there
was 20% variability between mice. For chronic antidepressant treat-
ment, mice were injected for 25 d with 12.5 mg/kg DMI or 0.9% saline in
themorning (9:00–10:00A.M.) and afternoon (4:00–5:00 P.M.). Testing
in the home, novel environment, and home environment occurred on
the last 3 d of injections.
For testing in the novel environment, mice were removed from the
home cage and placed in an empty standard cage with no bedding, which
was sprayed with a cleaner (Pine Sol) to emit a novel odor andwas placed
in a white box with bright light illumination. Latency to consume was
recorded. These mice were tested 3–6 h after DMI injection. Mice were
tested again in the home cage on the day after novel testing (Home 2),
under the same conditions as the first home test day (Home 1). In the
acute treatment experiment, training was performed as described above.
Mice were injected on the three testing days with 12.5 mg/kg DMI or
saline in themorning (9:00–10:00A.M.) and afternoon (4:00–5:00 P.M.)
and testing occurred 3–6 h after the morning injection of DMI. Thus, a
total of three doses of DMI were administered before exposure to the
novel environment.
Bromodeoxyuridine injections and tissue preparation. For evaluation of
the effect of DMI on short-term cell survival and bromodeoxyuridine
(BrdU) labeling, animals were administered saline or DMI (12.5 mg/kg,
i.p.; Sigma) twice daily for 38 d. Twenty-four hours after the last DMI or
saline injection,micewere administered BrdU twice daily (50mg/kg, i.p.;
Zymed, San Francisco, CA) for 4 d. Twenty-four hours after the last BrdU
injection, mice were anesthetized and transcardially perfused (0.1 M cold
PBS for 5 min followed by 4% cold paraformaldehyde for 15 min). A
second set of animals were allowed to survive for 6 weeks after the BrdU
injection, at which time they were anesthetized and perfused for evalua-
tion of long-term cell survival and phenotypic labeling. To determine the
effect of PCPA depletion on cell proliferation in CREB mutant and
WT littermates, mice were perfused 2 h after a single BrdU injection (100
mg/kg). All brains were postfixed overnight in paraformaldehyde at 4°C
and stored at 4°C in 30% sucrose. Serial sections of the brains were cut
(35 m sections) through the entire hippocampus using a cryostat, and
sections were stored in 0.1% NaN3/PBS. This BrdU-labeling paradigm
has been successfully used in multiple laboratories to accurately
quantify labeled cells. In addition, the use of confocal microscopy
with BrdU and neuronal and glial markers allows for additional eval-
uation of neurogenesis.
Immunohistochemistry. Free-floating sections were used in the deter-
mination of BrdU labeling. Series of every ninth section through the
hippocampus or subventricular zone of the lateral ventricle were pro-
cessed for BrdU immunohistochemistry (10–12 sections per brain).
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Using this spacing ensures that the same BrdU-positive cell will not be
counted twice. Sections evaluated for proliferation and neurogenesis
were heated for 20 min at 75°C in 0.01 M citric acid, pH 6.0, for antigen
retrieval. Afterwashing in 0.1MPBS, sectionswere permeabilized in 0.1%
trypsin with 0.1% CaCl2 for 10 min at room temperature. Sections were
rinsed with 0.1 M PBS and denatured with 2N HCl for 30 min at room
temperature. After blocking with 3% normal goat serum for 60 min at
room temperature, sections were incubated with anti-mouse BrdU (1:
150; Becton Dickinson, Franklin Lakes, NJ) with 0.5% Tween 20 over-
night at room temperature. Sectionswere then incubated for 60minwith
secondary antibody (1:200 biotinylated goat anti-mouse IgG; Sigma)
followed by quenching of endogenous peroxidases with 3% hydrogen
peroxide for 15min at room temperature. Secondary antibody signal was
amplified using an avidin–biotin complex (Vector Laboratories, Burlin-
game, CA) and visualized with DAB (Vector Laboratories).
For analysis of mature cell phenotypes, free-floating sections were
incubated in 2N HCl at 40°C for 20 min. Sections were rinsed in 0.02 M
potassium PBS (KPBS) and incubated with 0.3% Triton X-100 and 5%
normal goat serum in 0.02 M KPBS. Slices were incubated in primary
antibodies for 3 d at 4°C [1:100 anti-rat BrdU (Immunologicals Direct,
Raleigh, NC); 1:100 anti-mouse neuronal nuclei (NeuN) (Millipore, Te-
mecula, CA); and 1:2500 rabbit anti-S100 (Swant, Bellinzona, Switzer-
land)]. After rinsing in KPBS, a 1:200 dilution of secondary antibodies
Alexa 488 anti-rat IgG (in goat), Alexa 633 anti-rabbit IgG (in goat), and
Alexa 568 anti-mouse IgG (in goat; highly cross absorbed) was applied
for 2 h at room temperature (Invitrogen, Eugene, OR). After washing,
sections were slide-mounted with ProLong antifade solution (Invitro-
gen) and stored under dark conditions at 4°C.
Immunohistochemical quantitation. All BrdU-labeled cells in the den-
tate gyrus (granule cell layer) were counted in each section by an exper-
imenter blinded to the study code. To distinguish single cells within
clusters, all counts were performed at 40 and 100 under a light micro-
scope, omitting cells in the outermost focal plane. For the short-term
survival and proliferation cell counts (n  6–8 per group), a cell was
counted as being in the subgranular zone (SGZ) of the dentate gyrus if it
was touching, or within the SGZ. Cells that were located more than two
cells away from the SGZ were classified as hilar. For long-term survival
cell counts (n 6–8 per group), all BrdU-positive cells that were located
within the granule layer of the dentate gyrus were scored. Cells that were
locatedmore than two cells away from the granule layer were considered
hilar. The total number of BrdU-labeled cells per section was determined
andmultiplied by 9 to obtain the total number of cells per dentate gyrus.
For phenotypic analysis (n  6 per group), triple-labeled slices (BrdU,
NeuN, S100) were analyzed using a Leica (Bannockburn, IL) TCS-NT
confocal microscope, and images were captured using Leica confocal
software. At least 50 BrdU-positive cells per animal were further analyzed
using z-plane sectioning in 1 m steps to confirm the colocalization of
both BrdU and either of themarkersNeuNor S100. Cells were analyzed
in the xyz-plane using Imaris Software (Bitplane, Zurich, Switzerland).
Analysis of serotonin tissue content. Eighteen hours after the last injec-
tion of PCPA, mice were killed. Brains were rapidly microdissected, and
tissues were flash frozen in liquid nitrogen and stored at 80°C until
analysis. Individual brain regions were homogenized in a 100 M ethyl-
enediamine tetra-acetic acid solution dissolved in 0.1N perchloric acid
(15 l/mg of tissue). Samples were centrifuged at 2–8°C for 15 min at
15,000 rpm and supernatant was filtered using 0.45 m nylon Costar
(Cambridge, MA) Spin-X centrifuge filters. HPLC coupled with electro-
chemical detection (EC) was used to assay the filtered supernatant for
serotonin content.
The HPLC-EC system (Bioanalytical Systems, West Lafayette, IN)
consisted of a PM-80 pump, a Sample Sentinel autosampler, and a LC-4C
electrochemical detector. Twelvemicroliters of sample were injected and
pumped through a reverse-phase microbore column (ODS; 3 m; 1 
100mm; Bioanalytical Systems) at a flow rate of 0.6ml/min with electro-
detection at0.6 V. Separation for serotonin was accomplished by using
an HPLCmobile phase consisting of 90mM sodium acetate, 35 mM citric
acid, 0.34 mM EDTA, 1.2 mM sodium octyl sulfate, and 9% methanol
(v/v) with the addition of 2% dimethlyacetamide (v/v). HCl (12N) was
used to adjust the pH of the mobile phase to 4.2.
Statistics. For the BrdU immunohistochemistry, ANOVA and Fisher
post hoc tests were performed to establish statistical significance. For the
PCPA/neurogenesis experiment, we applied a mixed-model analysis
(SAS Linux, version 9; Proc Mixed) with genetic group as a between-
group factor and saline versus PCPA as a within-group factor. A post hoc
mixed-model contrast analysis was performed to test the hypothesis that
the CREB mutant mice show increased neurogenesis in comparison
with other groups, comparing the saline-treated CREB mutant mice
with all other groups. For the TST, we applied a mixed-model analysis
with genetic group as a between-group factor and saline versus DMI as a
within-group factor. A post hocmixed-model contrast analysis was per-
formed, comparing the saline-treated CREB mutant mice with all
other groups, to test the hypothesis that the CREB mutant mice
showed decreased immobility in comparison with other groups. For the
zero maze experiments, the ANOVA was performed on two genetic
groups (CREB, WT) by two treatment groups (SAL, DRUG), with
time in the open arm as a dependent variable. For the NIH paradigm
experiments, latency served as a dependent variable in a two genetic
groups (CREB, WT) by two treatment groups (SAL, DMI) ANOVA,
with condition (Home 1, Novel, Home 2) as a repeated-measures
(within) factor. The analysis was implemented in SAS (Linux, version 9;
Proc GLM).
Results
The antidepressant phenotype is associated with increased
cell proliferation in CREB-deficient mice
Chronic antidepressant treatment has been shown to increase
hippocampal neurogenesis. CREB mutant mice demonstrate
antidepressant-like responses in tests such as the FST and TST,
which are readouts of antidepressant efficacy. To determine
whether altered neurogenesis may underlie the antidepressant
phenotype, we examined granule cell proliferation and neuro-
genesis in wild-type and CREBmutant mice.
Animals were administered BrdU, and after different time
points of killing, the number of BrdU-positive cells in the adult
dentate gyrus was determined using immunohistochemical
detection.
At the 4 d time point, CREBmutant mice exhibited signif-
icantly more BrdU-positive cells than respective WT controls
(F(1,23)  5.24; p  0.0316), corresponding to a 52% increase
(Fig. 1A). In addition, chronic DMI treatment (5 weeks; 12.5
mg/kg, twice daily, i.p) was also examined.WTmice demonstrate
a significantly increased number of BrdU-positive cells in DMI
treated comparedwith saline controls by 51% (F(1,23) 4.73; p
0.0402). However, DMI treatment did not further increase the
number of BrdU-positive cells in CREB mutant mice com-
pared with saline-treatedmutant controls. The number of BrdU-
positive cells in saline-treated CREB-deficient mice was compa-
rable with that of DMI-treated WT mice.
The antidepressant phenotype is associated with increased
neurogenesis in CREB-deficient mice
To determine whether the newly born cells observed in WT and
CREB-deficient mice survive and differentiate into neurons, cells
labeled with BrdU were allowed to mature for 6 weeks. Saline-
treated CREB mutant mice exhibited significantly increased
numbers of BrdU-positive cells in the granule cell layer compared
withWT controls (F(1,24) 12.49; p 0.0017) (Fig. 1B), suggest-
ing that the many of the newly born cells survived for at least 6
weeks. In a similar manner, in WT mice, DMI treatment signifi-
cantly increased the number of BrdU-positive cells compared
with saline-treated WT controls (F(1,24)  5.098; p  0.0033)
(Fig. 1B) at this 6 week time point. However, in CREB
mutant mice, DMI had no additional effect on the number of
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BrdU-positive cells. Similar to previous reports, the total
number of BrdU-positive cells after 6 weeks was lower com-
pared with that at 24 h (Gould et al., 1999; Malberg et al., 2000;
Nakagawa et al., 2002a).
Phenotypic analysis of neurogenesis
To determine whether the BrdU-positive cells at the 6 week time
point have matured into neurons or glia, triple labeling with
BrdU, NeuN (marker for mature neurons), and S100 (glial
marker) was performed (Fig. 1C; supplemental Fig. 1, available at
www.jneurosci.org as supplemental material). Confocal micro-
scopic analysis with z-plane sectioning confirmed that themajor-
ity of surviving BrdU-positive cells matured into neurons in all
groups. Phenotypic analysis revealed that 67	 3% of the surviv-
ing BrdU-labeled cells in saline-treated WT mice expressed the
neuronal marker, NeuN. After DMI treatment, 66	 6% of sur-
viving BrdU-labeled cells exhibited a neuronal phenotype.
CREBmutantmice demonstrated similar patterns of neuronal
differentiation, with 70 	 4% of surviving BrdU-positive cells
maturing into neurons in saline controls, compared with 76 	
3% after DMI treatment. Fewer BrdU-labeled cells differentiated
into glial cells (Fig. 1C). In WT mice, saline controls demon-
strated 10 	 2% of BrdU-positive cells with glial phenotypes as
did 12 	 2% after DMI treatment. In saline-treated CREB-
deficient mice, 9 	 2% of BrdU-labeled cells expressed glial
markers, compared with 6 	 2% after DMI treatment. The re-
maining 18–24% of BrdU-labeled cells were not labeled with
either NeuN or S100, indicating a population of quiescent, un-
differentiated cells, or an existing cell type not labeled with the
antibodies used (Fig. 1C). BrdU, however, is not without its ca-
veats (Eisch, 2002). BrdU may be taken up not only by prolifer-
ating cells but also by cells undergoing repair. Although we can-
not rule out this possibility, it has been reported that this low level
of DNA incorporation is not easily detected using immunohisto-
chemical methods (Palmer et al., 2000).
Together, these data indicate that CREB deficiency produces
an increase inBrdU-positive cells that survive for 6weeks, and the
majority of those mature cells are neurons, indicating a net in-
crease in neurogenesis.
Serotonin depletion decreased cell proliferation in CREB-
deficient mice toWT levels
To examine the role of CREB deficiency and serotonin depletion
on cell proliferation, mice were treated with saline or PCPA, a
specific inhibitor of tryptophan hydroxylase, and killed 2 h after
the BrdU injection. This 2 h time point was chosen because it
represents one cell cycle of labeling (Cameron andMcKay, 2001)
and is thought to be an accurate measure of cell proliferation
(Malberg et al., 2000). As shown in Figure 2, CREB mutant
Figure 1. A–C, CREB deficiency increases the number of BrdU-positive cells at 4 d (A) and 6
weeks (B) in the dentate gyrus, with the majority of BrdU-positive cells differentiating into
neurons (C). Saline-treated CREBmutant mice demonstrated significantly increased num-
ber of BrdU-positive cells comparedwithWT controls (*p 0.05; n 6–8). This increasewas
maintained at the 6 week time point, at which the majority of the BrdU-positive cells matured
into neurons, indicating a net increase in neurogenesis in the CREB mutant mice. Chronic
DMI treatment significantly increased BrdU labeling in the dentate gyrus of WT mice at both
time points. Themajority of the surviving cellsmatured into neurons, indicating a DMI-induced
increase in neurogenesis in WT mice. In contrast to the DMI-induced increase in neurogenesis
seen in WT mice, the CREB mutant mice show no additional changes in BrdU labeling or
neurogenesis. Saline-treated CREB mutant mice demonstrated comparable numbers of
BrdU-positive cells and neurogenesis with that of DMI-treated WT controls (*p 0.05; n
6–9). In all groups, themajority of survivingBrdU-positive cells expressed theneuronalmarker,
NeuN. DMI treatment had no effect on the phenotypic distribution of surviving BrdU-positive
cells in WT or CREBmutant mice. Error bars indicate SEM.
Figure 2. Serotonin depletion reduced proliferation in CREBmutant mice to WT levels.
CREBmutant mice show a significant increase in cell proliferation compared with WT mice
( p 0.0494). Treatment with PCPA (250mg/kg) twice a day for 3 d reverses this increase
in cell proliferation in CREB mutant mice to WT levels ( p 0.0340), whereas PCPA
treatment had no effect on cell proliferation in WT mice (N 5– 6). Error bars indicate
SEM. *p 0.05; †p 0.05.
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mice show an increase in BrdU-labeled cells. PCPA treatment led
to a reversal of this increase in CREB mutant mice, whereas
PCPA had no significant effect on WT mice. A mixed model
statistical analysis foundmain effects for genetic group, (F(1,22)
4.35; p 0.0494) and for treatment, (F(1,22) 5.14; p 0.0340).
Post hoc contrast analysis revealed that the hypothesized
(CREB saline) group had significantly increased values com-
pared with all other groups, (F(1,23) 10.54; p 0.0036). These
data indicate that CREB deletion increases cell proliferation,
which can then be decreased toWT levels by serotonin depletion.
Serotonin depletion increased immobility times of CREB-
deficient mice toWT levels
To determine whether reversing the baseline increase in neuro-
genesis would have a functional behavioral correlate in the TST,
we administered PCPA to WT and CREB mutant mice and
measured the effect on immobility. Mixed-model analysis found
main effects for genetic group (F(1,22) 6.18; p 0.0210) and for
treatment, (F(1,22)  9.51; p  0.0054). As shown in Figure 3,
CREBmutantmice had significantly reduced values compared
with all other groups (F(1,24) 10.10; p 0.0041). This increase
demonstrates that the relationship between neurogenesis and be-
havior in these mice is maintained after serotonin depletion and
supports a causal relationship between neurogenesis and behav-
ior in these mice.
Serotonin depletion has no effect on anxiety in the elevated
zero maze
In addition to an antidepressant phenotype, CREB mutant
mice also exhibit increased baseline anxiety (Graves et al., 2002;
Hebda-Bauer et al., 2004). To determine whether the reversal of
neurogenesis and the antidepressant phenotype is accompanied
by a decrease in anxiety, we evaluated mice in the elevated zero
maze after serotonin depletion. As shown in Figure 4, treatment
with PCPA did not have an effect on time spent in the open arm
in either WT or CREBmutant mice (F(1,30) 0.06; p 0.05),
with the latter once again demonstrating a baseline increase in
anxiety (F(1,30) 6.76; p 0.0143).
Serotonin levels are equivalent inWT and CREB
mutant mice
A possible explanation for the phenotype observed in CREB
mutant mice would be that the animals have altered serotonin
levels. Therefore, we measured tissue serotonin content in these
animals. Two-way ANOVAs demonstrate that the baseline sero-
tonin level in CREB mutant mice did not differ from that of
WT mice throughout the amygdala, cortex, hippocampus, nu-
cleus accumbens, and raphe (Table 1). 5-Hydroxy-indoleacetic
acid (5-HIAA)/5-HT ratios were measured as a marker for turn-
over, and no significant differences between mutants and WT
were found in the amygdala, cortex, hippocampus, nucleus ac-
cumbens, and raphe (Table 1). This suggests that baseline alter-
ations in behavior and neurogenesis in CREB mice are not
attributable to changes in serotonin or its turnover. Stimulated
serotonin release was also equivalent inWT andCREBmutant
mice (supplemental Fig. 2, available at www.jneurosci.org as sup-
plemental material), again demonstrating that CREB deficiency
throughout development does not impact serotoninmetabolism.
The efficacy of PCPA treatment in these experiments was verified
by a 72–90% reduction in serotonin levels in comparison with
saline-treated animals: F(1,29)  213.09, p  0.0001; F(1,29) 
217.51, p 0.0001; F(1,29) 148.14, p 0.0001; F(1,27) 24.54,
p 0.0001; F(1,28) 122.10, p 0.0001, measured in the amyg-
dala, cortex, hippocampus, nucleus accumbens, and raphe, re-
spectively. The magnitude of PCPA depletion in discrete brain
regions was equivalent across genotypes.
WT and CREBmutant mice respond to chronic
antidepressant treatment in the NIH paradigm
The NIH paradigm has been reported to be sensitive to chronic,
but not acute, antidepressant treatment. Therefore, we used this
paradigm to determine whether CREB mutant mice respond
to chronic AD treatment. As shown in Figure 5,DMI significantly
reduced the latency to consume the food in a novel environment
for both WT and CREBmutant mice. There was a main effect
of genotypewithmutants showing overall higher latencies (F(1,34)
 4.78; p  0.0358), an effect of treatment with treated mice
showing lower latencies (F(1,34)  11.11; p  0.0021), and no
genotype by treatment interaction (F(1,34)  1.35; p  0.2541).
Two-way ANOVAwith repeatedmeasures revealed amain effect
of condition with longer latencies for the novel compared with
home conditions (F(2,68)  58.12; p  0.0001), a genotype by
condition interaction with higher latencies for CREB mutant
mice compared with WT in the novel condition (F(2,68)  4.68;
p  0.0125), a treatment by condition interaction with lower
latencies for DMI-treated mice in the novel condition (F(2,68) 
12.21; p  0.000), but no three-way interaction (F(2,68)  1.42;
p  0.2476). In addition, CREB mutant mice had generally
increased latencies in the novel environment compared withWT
mice, consistent with the anxiogenic phenotype observed in the
zero maze (Fig. 4). Of the 40 mice tested, 2 were eliminated from
Figure 3. Serotonin depletion reversed the antidepressant phenotype of CREB mutant
mice in the TST. Mice were treated with PCPA twice a day for 3 d. Immobility in the TST was
measured 18 h after the last injection. The TST revealed a significant effect of genotype and
treatment, with the PCPA-treated CREB mutant mice returning to WT levels (n 4–8).
Error bars indicate SEM. *p 0.05; †p 0.05.
Figure 4. Serotonin depletion does not have an effect on anxiety in the elevated zeromaze.
Mice were treated with PCPA and tested in the elevated zero maze 18 h after the last dose.
CREB mutant mice spent significantly less time in the open arm of the maze, reflecting a
proanxietyphenotype. TreatmentwithPCPAdidnot alter anxiety levels in eitherWTor CREB
mutant mice (n 8–9). Error bars indicate SEM. *p 0.05.
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analysis for having latency scores less than or greater than 2 SDs
from the mean.
CREBmutant mice respond to acute antidepressant
treatment in the NIH paradigm
To control for the acute effects of AD in this paradigm,mice were
trained to consume a highly palatable food, and then injected on
the three testing days with 12.5mg/kgDMI or saline in themorn-
ing (9:00–10:00 A.M.) and afternoon (4:00–5:00 P.M.). Testing
occurred at exactly the same time point after DMI as described
for the chronic experiment. As expected, acute DMI had no effect
on altering latency to consume food in a novel environment in
WTmice. In contrast, the time required byCREBmutantmice
to investigate and consume the food was significantly reduced
(Fig. 6). The overall main effects of genetic group and treatment
group were replicated, with mutants showing overall higher la-
tencies (F(1,24)  4.90; p  0.0366) and treated mice showing
lower latencies (F(1,24)  9.40; p  0.0053), but this time the
genotype by treatment interaction was also significant (F(1,24)
6.18; p 0.0202). There was no treatment effect in theWTmice.
Two-way ANOVA with repeated measures showed a main effect
of condition (F(2,48) 89.98; p 0.0001) with longer latencies in
the novel condition, a genetic group by condition interaction
(F(2,48) 4.64; p 0.0143) with longer latencies in the CREB

mutant mice for the novel condition, a treatment by condition
interaction (F(2,48)  9.86; p  0.0003) with longer latencies in
untreated than treated mice, and these were accounted for by a
three-way interaction (F(2,48) 6.86; p 0.0024). The three-way
interaction indicates an effect of acute treatment in the CREB
mutantmice relative to the absence of treatment effects in theWT
mice. As seen previously (Fig. 5), saline-treated CREBmutant
mice demonstrated a significant increase in latency to approach
the food and eat over WT mice. Of the 33 mice tested, 5 were
eliminated from analysis for having latency scores less than or
greater than 2 SDs from the mean, or for failing to reach baseline
latency.
Increased baseline anxiety in the elevated zero maze is not
reversed in the CREBmutant mice by acute antidepressant
treatment
To determine whether DMI had an anxiolytic-like effect in the
CREB mutant mice, we tested this compound in the elevated
zero maze in WT and CREB mutant mice. CREB mutant
mice spent significantly less time in the open arm relative to WT
mice, reflective of an anxiety-like phenotype. However, this be-
havior was not mitigated by acute treatment with DMI (Fig. 7A).
Two-way ANOVA revealed a main effect of genotype (F(1,34) 
20.71; p 0.0001) on time spent in the open arm. Neither treat-
ment nor genotype by treatment interaction approached signifi-
cance on this parameter. In regard to ethologically relevant pa-
rameters and latency to enter the open arm (Fig. 7B,C), two-way
ANOVAs demonstrated a significant effect of genotype on
stretch-attend-posture (F(1,34)  5.93; p  0.02), head dips
(F(1,34)  10.904; p  0.0023), and latency (F(1,34)  4.237; p 
0.0473), but not on rearing (F(1,34) 0.026; p 0.05). There was
no significant effect of treatment or genotype by treatment inter-
actions on any of these parameters, including head dip, SAP,
latency, or rearing. Thus, the acute effect of DMI in CREB
mutant mice is specific to an antidepressant effect in these mice.
Table 1. Serotonin tissue content (picograms per microliter) and turnover (5-HIAA/5-HT)
Brain region
WT-saline CREB-saline WT-PCPA CREB-PCPA
Levels Turnover Levels Turnover Levels Turnover Levels Turnover
Amygdala 367	 22 0.52	 0.03 338	 24 0.53	 0.03 62	 4 0.24	 0.01 57	 6 0.25	 0.02
Frontal cortex 223	 6 0.53	 0.02 196	 11 0.52	 0.02 54	 21 0.33	 0.13 34	 8 0.19	 0.03
Hippocampus 653	 59 1.07	 0.05 690	 59 1.14	 0.08 82	 7 0.36	 0.03 64	 9 0.32	 0.05
Nucleus accumbens 195	 11 0.52	 0.06 198	 35 0.42	 0.03 41	 7 0.23	 0.04 37	 9 0.18	 0.04
Brainstem 457	 36 1.04	 0.09 440	 38 1.02	 0.07 128	 22 0.92	 0.05 124	 16 0.69	 0.07
Mice (n 8–9 per group) were killed 18 h after the last injection of PCPA. Brains were microdissected and HPLC coupled with EC was used to assay the filtered supernatant for serotonin content. Baseline serotonin levels, turnover, and
depletion in CREBmutant mice did not differ from that of WT mice throughout the amygdala, cortex, hippocampus, nucleus accumbens, and raphe.
Figure 5. Chronic DMI treatment decreased the latency to consume peanut butter chips in
the novel environment in both WT and CREBmutant mice. Mean latencies to consume the
highly palatable food in the home and novel environment are shown. Mice were treated with
DMI (12.5 mg/kg) for 25 d before testing. There was a decreased latency in DMI relative to
saline-treated animals (*p 0.004). There was an overall increased latency inmutant relative
to WT animals (p 0.04) (n 9–10). Error bars indicate SEM.
Figure 6. CREBmutant mice demonstrated a significant decrease in latency in response
to acute DMI treatment, whereas there was no effect of treatment in the WT mice. Mean
latencies to consume the highly palatable food in the home and novel environment are shown.
Mice (n 9–10 per group) received a dose of DMI (12.5mg/kg) in themorning and evening of
eachof the 3dof testing. A total of three doses of DMIwas receivedbefore exposure to thenovel
environment. There was a decreased latency in DMI relative to saline-treated CREBmutant
mice (*p 0.01). Therewas also an increased latency inmutant relative toWT animals (p
0.04) (n 7). Error bars indicate SEM.
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Discussion
The notion that reduced hippocampal neurogenesis is involved
in the pathophysiology of depression has gained traction in re-
cent years (Dranovsky and Hen, 2006; Duman and Monteggia,
2006). AD treatment is thought to ameliorate the symptoms of
depression by reversing this process. However, the connection
between neurogenesis, its molecular underpinnings, and behav-
ioral consequences are mostly correlative. The FST and the TST
are commonly used to assess antidepressant effects of drugs and,
more recently, depressive phenotypes in mice (Cryan et al.,
2002). CREBmutant mice demonstrated decreased immobil-
ity in both of these paradigms, which was further reduced by ADs
(Conti et al., 2002), suggesting an “antidepressant state” that is
still sensitive to drug treatment. Changes in homecage motor
activity or swimming behavior were not found (Walters and
Blendy, 2001; Graves et al., 2002), and therefore do not account
for these findings. To gather information on possible biological
substrates responsible for the antidepressant phenotype of
CREB mutant mice, we examined neurogenesis, a parameter
altered by chronic AD treatment.
Our data demonstrate that constitutive reduction in CREB
protein enhances BrdU-labeled cell proliferation. Furthermore,
the majority of these cells mature into neurons, indicating that
CREB-deficientmice have increased proliferation and neurogen-
esis, comparable with levels observed in WT mice receiving
chronic AD treatment (Malberg et al., 2000). However, chronic
treatment with DMI did not further increase hippocampal neu-
rogenesis in CREB-deficient mice. This lack of an additional
DMI-induced increase in neurogenesis in the CREBmutantmice
may be attributable to inherent proliferative limits of the hip-
pocampus. In previous rat studies, treatment with fluoxetine in-
creased the number of BrdU-labeled cells by 20–40%, whereas
electroconvulsive seizure caused a50% increase (Malberg et al.,
2000; Warner-Schmidt and Duman, 2007). Because CREB
mutant mice demonstrate an 52% increase in BrdU-positive
cells comparedwithWTmice, it is possible that the hippocampus
has reached the upper limits of its neurogenic capacity. Indeed, in
anothermousemodel showing 20% elevation in baseline levels of
hippocampal neurogenesis, chronic treatment with DMI and
citalopram failed to further increase neurogenesis (Morcuende et
al., 2003).
Our finding of increased levels of hippocampal neurogenesis
in the CREB-deficient mice (Fig. 1) differs from the report of
decreased levels in a transgenic mouse expressing dominant-
negative CREB (mCREB) (Nakagawa et al., 2002a). However by
binding toCRE sequences inDNA,mCREBmay target genes that
are not normally regulated by CREB (Blendy, 2006), thereby al-
tering neurogenesis through other mechanisms. CREB manipu-
lations in other mouse models, and viral vector-mediated gene
overexpression, have led to behavioral changes in depression-
related behavioral paradigms as well. Acute overexpression of
CREB in the nucleus accumbens of rats leads to a pro-depressant
response in the FST, and a decrease of CREBmediated by expres-
sion of a dominant-negative formof the protein in rats leads to an
antidepressant-like effect (Pliakas et al., 2001), with similar ef-
fects found in the learned helplessness paradigm inmice and rats
(Newton et al., 2002). However, acute overexpression of CREB in
the hippocampus leads to an antidepressant effect in the FST
(Chen et al., 2001). To date, neither levels of neurogenesis nor
behavior in paradigms that are sensitive to chronic AD treatment
have been evaluated in these models.
To investigate a more causal relationship between neurogen-
esis, behavior, and CREB, we depleted mice of serotonin with
PCPA. Serotonin is thought to play a role in neurogenesis (Gas-
par et al., 2003), and previous studies have reported either no
change or a decrease in proliferation in rats treated with PCPA
(Brezun and Daszuta, 1999, 2000; Banasr et al., 2001; Huang and
Herbert, 2005; Jha et al., 2006). Serotonin has been implicated in
both the pathophysiology and treatment of depression. There-
fore, we wanted to examine the role of serotonin in maintaining
cell proliferation and antidepressant behavior in mice that dem-
onstrate an antidepressant-like phenotype and increased levels of
neurogenesis. We found that serotonin depletion with PCPA re-
versed the antidepressant phenotype of CREBmutantmice on
both a cellular (Fig. 2) and behavioral (Fig. 3) level, whereas it had
no effect on WT mice. Our data support previous findings that
PCPA depletion does not have an effect on immobility in WT
mice in the TST (O’Leary et al., 2007). Of interest, serotonin
levels and turnover did not differ betweenWT and CREBmu-
tant mice (Table 1) and stimulated release of serotonin was also
consistent between the two groups (supplemental Fig. 2, available
at www.jneurosci.org as supplemental material). However, the
serotonergic tone in CREBmutant mice, although not differ-
ent in magnitude, provides a critical stimulus that causes mice to
behave at baseline as though they have undergone chronic AD
treatment. Additional studies are warranted to investigate the
nature of this complex interaction.
In addition to an antidepressant-like phenotype, CREB
mutant mice demonstrate increased levels of anxiety (Graves et
al., 2002; Hebda-Bauer et al., 2004). This anxiety phenotype is
also evident in the NIH paradigm with CREB mutant mice
showing increased latency to feed in a novel environment (Figs. 5,
6). Serotonin depletion does not reverse the anxiogenic-like phe-
notype in the elevated zero maze (Fig. 4), further emphasizing a
specific correlation between the antidepressant phenotype and
neurogenesis. Whether PCPA treatment reduces the latency to
feed in a novel environment in CREB mutant remains to be
seen. Unfortunately, serotonin depletion produces an anxiolytic,
Figure7. A, CREBmutantmice showed significantly reduced time spent in the open arm
relative to WT (p 0.0001) in the elevated zero maze. This reduction was not affected by
acute treatment with DMI. Mice (n 9–10 per group) received a total of three doses of DMI
(12.5 mg/kg) before testing, with the same schedule used in the NIH. B, In regard to ethologi-
cally relevant parameters, there is a significant effect of genotype on stretch-attend-posture,
and head dips (*p 0.05), but not on rearing. C, CREB mutant mice demonstrated an
increased latency to enter the open arm (p 0.05). Error bars indicate SEM.
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or decreased hyponeophagia effect in the NIH test in rat (Bech-
tholt et al., 2007), making it difficult to interpret baseline effects
in CREBmutant mice.
Overall, the antidepressant-like phenotypemay at first seemat
odds with the anxiety phenotype. However, 5-HT1A knock-out
mice also demonstrate an antidepressant phenotype in combina-
tion with an increased level of anxiety (Heisler et al., 1998; Parks
et al., 1998; Ramboz et al., 1998), suggesting that endophenotypes
related to comorbid neuropsychiatric disorders may be uncou-
pled in animal models.
To date, the significance of CREB in mediating any behaviors
associated with chronic AD treatment have not been investigated
in part because of the lack of well validated behavioral paradigms
designed to evaluate chronic AD effects. Therefore, to examine
the functional significance of increased neurogenesis as well as
gain additional insight into possible behavioral implications of
this alteration, we tested the CREB mutant mice in the NIH
paradigm. In this paradigm, exposure to a novel environment
elicits an increased latency to consume a highly palatable food.
This increase in latency is reversed by chronic, but not short-
term,AD treatment (Merali et al., 2003),making it a usefulmodel
to understand molecular and cellular changes underlying the be-
havioral response to chronic AD treatment. It is closely related to
the NSF paradigm, with the latter using food deprivation to in-
duce consumption of regular food. A limitation of both the TST
and FST is their responsiveness to acute administration of anti-
depressants. Clinically, weeks of treatment are needed to amelio-
rate behavioral symptoms, reflecting the need for long-term tran-
scriptional and cellular changes. Using the NIH paradigm, the
present data demonstrate that CREBmutant mice respond to
acute AD treatment, an effect not seen in WT mice.
Acute anxiolytic compounds are effective in the NIH para-
digm (Merali et al., 2003); thus the acute effect ofDMI in theNIH
test in CREB mutant mice could be interpreted as an
anxiolytic-like response. Caveats associated with constitutive
knock-outmousemodels range from unexpected compensation,
effects on other gene products throughout development, and al-
tered endocrine and neuronal feedback. These types of alter-
ations in the CREBmutantmice could result in amodification
of pharmacological profiles of classic AD. To determine whether
DMI is exerting anxiolytic effects in CREB mutant mice, we
examined its effects onWTandCREBmutantmice in a second
test for anxiety, the elevated zero maze. Few studies have exam-
ined the response to acute or chronic AD treatment in the ele-
vated plus and elevated zero maze and results have been highly
variable. Depending on the test used and the AD administered,
many studies have reported no effect or an anxiogenic effect
(Borsini et al., 2002). Our results replicate the lack of efficacy of
acute DMI treatment in the elevated zero maze in WT mice.
Moreover, DMI is not effective in reducing anxiety in CREB
mutant mice, suggesting the acute action of DMI in the NIH test
may be more related to the antidepressant responsive aspects of
this paradigm.
AD effects in the NIH paradigm may require cellular changes
in response to AD treatment as well. In the NSF paradigm, it has
been shown that neurogenesis is necessary for a behavioral re-
sponse to AD treatment (Santarelli et al., 2003). Thus, the in-
creased levels of neurogenesis in CREBmutant mice may pro-
vide a mechanism for the rapid onset of response to treatment
effects in thesemice.Without the usual requirement of increasing
neurogenesis, AD drugs may exert behavioral effects more rap-
idly in an animal that has been “primed” to respond to these
compounds. Although CREB activation after AD treatment may
serve to initiate mechanisms that underlie the lengthy time
course needed to achieve the behavioral effect inWTmice, under
conditions in which CREB is constitutively deleted these mecha-
nisms are already engaged. Our findings have potential clinical
implications, because the delayed onset of a behavioral response
to AD treatment poses a challenge. Identification of mechanisms
through which CREB influences neurogenesis and the behavioral
response to AD treatment may identify new targets for faster-
acting therapies for depression.
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